Natasha Leskovsek

Cooley advised RayzeBio, a targeted radiopharmaceutical company developing an innovative pipeline against solid tumor targets, on its upsized $357.6 million initial public offering.

Cooley advised the underwriters on the $250.1 million initial public offering of Neumora Therapeutics, a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed.

Cooley advised TriSalus Life Sciences, an oncology company with a focus on treatments for patients with liver and pancreatic tumors, on its merger with MedTech Acquisition Corporation.

Cooley advised Tentarix Biotherapeutics and three of its subsidiaries on three multiyear collaborations with Gilead Sciences.

Cooley advised Senti Biosciences, a biotechnology company, on its sale of certain assets – including its manufacturing facility and chemistry, manufacturing, and controls capabilities – to Celadon Partners.